A secondary analysis of economic outcomes–related data from the Rehabilitation
Therapy in Older Acute Heart Failure Patients trial attempted to answer if a novel 12-week rehabilitation intervention held cost-effective value.
Because its long-term value remains uncertain, the cost-effectiveness of a novel 12-week intervention for patients with acute heart failure (HF)—especially those with HF with preserved ejection fraction (HFpEF)—that was investigated in the Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial needs additional study, reports JAMA Cardiology.
This intervention began during hospitalization and comprised 36 sessions that took place over 12 weeks, for a 1:1 session 3 days per week. The patients randomized to this intervention supplemented it with home exercise that included walking and strengthening exercises and discussed their adherence through monthly phone calls.
“The intervention may…
